Tap your goals. We read the pathways behind them and build one custom combo that covers the most it can — ready to order in under a minute.

• Fasting insulin — No professional body publishes a fasting-insulin reference interval, and the reason is itself published: insulin immunoassays are not standardised. Measured against isotope-dilution mass spectrometry, assay deviation ran from −298.2 to +302.6 pmol/L. A single number here would be true only of one analyser.
• Advanced glycation (AGEs) — No society, national study or large cohort publishes a reference interval for circulating advanced glycation end-products. Blood AGE testing is not one test — CML, pentosidine, MG-H1 and total fluorescent AGEs report on different scales — so no figure would be comparable to a laboratory report.
• Lipoprotein lipase activity — Lipoprotein lipase activity is a post-heparin assay requiring an intravenous heparin challenge. No society guideline or reference-interval study publishes a range, and the one laboratory service document found states on the same page that its range is method dependent.
• Growth hormone — Growth hormone is secreted in pulses, which is why diagnosis rests on provocative testing rather than a resting draw. Every published growth-hormone figure is a stimulation-test cut-point for suspected pituitary disease. None of them applies to a blood draw, and no reference interval exists.
• Cortisol — No named body publishes a reference interval for morning serum cortisol. The guideline gives adrenal-insufficiency cut-points only, marks them assay dependent, and calls the rule-out values controversial — the assay-specific low limit alone spans 418–574 nmol/L.
• Uric acid — The published urate numbers are treatment targets measured in patients with diagnosed gout already on urate-lowering therapy. They are not a general-population reference interval, and no qualifying one could be retrieved, so no number is held against yours here.
• Bone density — BONE DENSITY IS NOT A BLOOD MARKER - it is a DXA measurement, and the number is a T-score, not a concentration; it belongs on a bloodwork page only if that is made explicit. The reference standard from which the T-score is calculated is, per ISCD 2023, 'the female, white, age 20-29 years, NHANES III database'; manufacturers should use NHANES III for femoral neck and total hip T-scores and their own databases for lumbar spine. Site rules (ISCD 2023): 'Use femoral neck or total hip, whichever is lowest'; 'In certain circumstances the 33% radius (also called 1/3 radius) may be utilized'; Ward's area and the greater trochanter 'should not be used for diagnosis'. ISCD states 'The WHO densitometric classification is applicable' and retains the term 'osteopenia' while preferring 'low bone mass' or 'low bone density', but it does NOT itself print the normal or low-bone-mass cut-points. Honest GAP: no 'normal' band (commonly quoted as a T-score of -1.0 or above) is written here, because the four-category WHO table originates in the WHO Study Group report (WHO Technical Report Series 843, 1994; synopsis Kanis, Osteoporos Int 1994;4:368-381, DOI 10.1007/BF01622200) which could not be retrieved in full - the Sheffield WHO Collaborating Centre PDF now redirects, the WHO IRIS bitstream for Technical Report Series 921 (2003) errored, and neither the 2018 AHRQ evidence review, the 2019 Endocrine Society osteoporosis guideline, the 2013 IOF epidemiology recommendations nor ISCD 2023 prints the normal band. The osteopenia band above comes from the USPSTF's 2002 statement, retrieved from a web archive because the live AHRQ page has moved; it is expressed in SD below the young-adult-woman mean rather than as a labelled T-score range, and it is stated for postmenopausal women. A T-score alone does not diagnose osteoporosis in premenopausal women or men under 50, for whom ISCD uses Z-scores.

Each of these still reads a pathway, and each stays selectable from its own page. A number with nothing published to hold it against is not a number this panel will pretend to read.